What is Orexin-A?
Orexin-A, also known as hypocretin-1, is a hypothalamic signaling peptide. The foundational paper identified orexin peptides and receptors and studied feeding responses in rats.
Biological role or research focus
Hypothalamic feeding and arousal research.
The featured discovery paper does not establish treatment of insomnia, narcolepsy, or human performance enhancement.
Role reference: Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. · 1998 ↗
Names you may encounter
Hypocretin-1 · Orexin A
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Orexin / hypocretin neuropeptide
- Research focus
- Hypothalamic feeding and arousal research
- Featured evidence
- Animal discovery study
- Source check
- October 4, 2026
Quick answers
- Is Orexin-A FDA approved?
- No. No FDA-approved drug contains Orexin-A. Source ↗
- Is Orexin-A safe?
- Not an approved drug. A few tiny short studies gave orexin-A to people with narcolepsy or healthy men; none was designed to define safety, so risks remain unknown. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Orexin-A banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Orexin discovery and feeding experiments (1998) | Animal discovery study | Rat brain preparations and rats in feeding experiments. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Animal discovery study · 1998
Orexin discovery and feeding experiments
What did this publication test, and what did it find?
- Population / model
- Rat brain preparations and rats in feeding experiments.
- Study design
- Peptide and receptor identification, precursor-expression measurements, and central-administration experiments.
- Main finding
- Central orexin administration promoted feeding, and fasting increased precursor expression in the reported experiments.
- Limits & context
- The featured discovery paper does not establish treatment of insomnia, narcolepsy, or human performance enhancement.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
6 registered studies name Orexin-A as an intervention; 0 are recruiting or under way, 0 have not started recruiting yet, 3 completed and 3 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence NCT05615584 · University Hospital, Montpellier | Completed | Not applicable | 2023-02-15 | 117 |
| Digital Addiction, Sleep Quality and Orexin-A Level NCT06738524 · Amasya University | Completed | Not applicable | 2024-02-01 | 42 |
| Orexin-A Levels in Insomnia Patients NCT05664295 · Muğla Sıtkı Koçman University | Completed | 2022-12-30 | 60 | |
| The Value of Combined Detection of Orexin-A, HLA Gene, PSG and MSLT in the Evaluation of Patients With Narcolepsy NCT04940806 · Qianfoshan Hospital | Status unknown | 2021-05-01 | 120 | |
| Plasma Orexin A and mRNA Expression Levels of Pre-pro-orexin Gene in Attention-Deficit Hyperactivity Disorder NCT02074176 · National Taiwan University Hospital | Status unknown | 2011-01 | 50 | |
| Difference of Plasma Orexin A Levels Between Elderly and Young Patients at Emergence NCT01478906 · Xijing Hospital | Status unknown | 2011-07 | 40 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Orexin-A alleviates astrocytic apoptosis and inflammation via inhibiting OX1R-mediated NF-κB and MAPK signaling pathways in cerebral ischemia/reperfusion injury. ↗
Biochimica et biophysica acta. Molecular basis of disease · 2021 Nov 1 · Journal Article, Research Support, Non-U.S. Gov't
Therapeutic effects of orexin-A in sepsis-associated encephalopathy in mice. ↗
Journal of neuroinflammation · 2024 May 17 · Journal Article
Read available full text ↗
Orexin-A and Circadian Disruption in Alzheimer's Disease: Implications for Amyloid-Beta Pathology. ↗
Molecular neurobiology · 2025 Dec 3 · Journal Article
Bidirectional gut-brain communication: A role for orexin-A. ↗
Neurochemistry international · 2020 Dec · Journal Article, Research Support, Non-U.S. Gov't, Review
Risks & interactions
Not an approved drug. A few tiny short studies gave orexin-A to people with narcolepsy or healthy men; none was designed to define safety, so risks remain unknown.
Small crossover studies (8 to 14 people with narcolepsy; 10 healthy men) used single exposures. One pilot found raised sympathetic nerve activity, and its authors called for study of a link to high blood pressure. No repeated-use safety data were found.
Unassessed: little human safety data
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Orexin-A on sleep, wakefulness and attention in narcolepsy (2014) ↗ · Hypocretin-1 (orexin A) on sleep in narcolepsy (2011) ↗ · Orexin A modulates sympathetic vascular tone: pilot in healthy men (2022) ↗ · Orexins and orexin receptors (Cell, 1998) ↗
Safety & what remains unknown
Animal central-administration findings cannot determine human exposure or systemic safety.
Evidence boundaries
The featured discovery paper does not establish treatment of insomnia, narcolepsy, or human performance enhancement.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
This profile distinguishes an endogenous signaling peptide from medicines targeting its receptors. A receptor antagonist and orexin-A are different interventions.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Biology & proposed mechanism
The discovery work linked orexin signaling to hypothalamic physiology. Later sleep applications need their own evidence rather than being assumed from the peptide’s name.
Questions worth asking
- Is orexin-A equivalent to an orexin-receptor sleep medicine?
- What material, population, and route were actually studied?
- The featured discovery paper does not establish treatment of insomnia, narcolepsy, or human performance enhancement.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is orexin-A equivalent to an orexin-receptor sleep medicine?
No. The peptide and a medicine blocking or stimulating a receptor are different interventions.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
